Tag

A1c

All articles tagged with #a1c

wellness2 days ago•81 min saved

7 Foods That May Rapidly Lower A1C and Help Reclaim Prediabetes

A dietitian-backed wellness piece identifies seven foods that can significantly lower A1C and help reverse prediabetes when included in a balanced diet rich in fiber and protein: psyllium fiber, pistachios, apple cider vinegar, cinnamon, strawberries, oats, and beans/peas/lentils. The article emphasizes pairing these foods with protein and vegetables, mindful portion sizes, and adding physical activity after meals to further stabilize blood sugar and improve overall metabolic health.

via Woman's World|

#a1c #blood-sugar #diabetes

healthcare1 month ago•23 min saved

Lilly's retatrutide shows sweeping obesity and cardiometabolic benefits in Phase 3 trials

Lilly revealed that retatrutide, a once‑weekly GIP/GLP‑1/glucagon triple agonist, produced major weight loss (up to 70.3 lbs, 28.3% at 80 weeks) and strong A1C reductions (up to 2.0%) in Phase 3 TRIUMPH-1 and TRANSCEND-T2D-1, plus meaningful knee osteoarthritis pain and sleep apnea improvements, suggesting potential to treat obesity and its related complications; results were presented at the ADA 86th Scientific Sessions and published in The Lancet.

via investor.lilly.com|

#a1c #healthcare #knee-osteoarthritis

health3 months ago•4 min saved

Jelly Roll’s labs reveal why your family might need more than a standard checkup

Jelly Roll’s blood work showed alarming problems: very high insulin, low testosterone, high cholesterol, and an A1C in diabetes territory—issues not caught by standard annual panels. The piece argues for asking primary care doctors to order expanded tests (A1C, fasting insulin, testosterone, lipid panel, thyroid TSH) and to review results in detail, as well as considering direct-to-consumer panels, since insurance coverage is variable. The message: document personal health history to qualify for expanded testing and retest if results are borderline, because these tests can reveal hidden metabolic risks early.

via Miami Herald|

#a1c #health #insulin

health3 months ago•7 min saved

Lilly's retatrutide delivers strong A1C drops and meaningful weight loss in first Phase 3 Type 2 diabetes trial

Lilly reports positive topline results from TRANSCEND-T2D-1, a Phase 3 trial of retatrutide, a once-weekly triple hormone receptor agonist (GIP, GLP-1, glucagon), showing up to a 2.0% reduction in A1C and about 17% body-weight loss at 40 weeks versus placebo, with dose-dependent effects and continued weight loss through the treatment period. The most common side effects were gastrointestinal (nausea, diarrhea, vomiting) largely during dose escalation, with some dysesthesia but generally manageable. Results met primary and key secondary endpoints and will be detailed at the ADA Scientific Sessions in June; Lilly plans to publish additional data from the retatrutide program over the next year.

via Eli Lilly|

#a1c #health #phase-3

business3 months ago•4 min saved

Lilly's Triple-Hormone Drug Retatrutide Delivers Promising Diabetes, Weight Loss in Phase 3 Trial

Eli Lilly's next‑generation obesity drug retatrutide showed strong Phase 3 results in Type 2 diabetes, lowering A1C by about 1.7%–2% at 40 weeks and achieving roughly 16.8% weight loss at the highest dose among patients who stayed on treatment, with a tolerable safety profile. The company has not filed for approval yet and plans additional Phase 3 trials, pursuing retatrutide as a key pillar of its obesity/diabetes portfolio alongside Zepbound and orforglipron, as Novo Nordisk races to catch up.

via CNBC|

#a1c #business #eli-lilly

health3 years ago•4 min saved

The Long-Term Consequences of Type 2 Diabetes in Children

Children with type 2 diabetes face a high incidence of vascular complications as they age into young adulthood, with an 80% incidence of at least one complication during up to 15 years of follow-up. Arterial stiffness and worsened cardiac function often appear in these children within 2-5 years of diagnosis and seem driven in part by the development of hypertension and worsening A1c levels. The dire prognosis is a reason to aggressively treat these patients with antidiabetic medications from drug classes with proven cardiovascular disease protection, specifically sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) agonists.

via Medscape|

#a1c #antidiabetic-medications #cardiovascular-disease